The USFDA conducted inspections at Torrent Pharma's Indrad facility and Lupin's injectable unit in Nagpur. Torrent Pharma received a form 483 with five observations, while Lupin's unit had zero observations. Both inspections have now been closed.
Global pharma major Lupin announced that the United States Food and Drug Administration (USFDA) completed an inspection of its injectable facility in Nagpur, concluding with zero observations @koul_sanket #lupin #pharma #fda https://t.co/4LWSWcduV9
News Alert | Lupin announces closure of USFDA inspection at its injectable facility with zero 483 observations @LupinIndia https://t.co/5CoGTFxaRO
#JustIN | US FDA issues form 483 with zero observations for #Lupin’s injectable unit in Nagpur, this marks the closure of inspection at the unit Injectable Unit In Nagpur was inspected by US FDA from June 10 -13, 2024 https://t.co/O8RFDktkTG
U.S. FDA inspection at #TorrentPharma's Indrad facility in Gujarat closes with 5 observations: Exchange filing
Torrent Pharma: USFDA conducted a pre-approval inspection and a GMP inspection at its Indrad facility between June 3 to June 12, 2024. At the end of the inspection, the company has been issued a form 483 with five observations.